Tuberculosis (TB) remains the top cause of death from a single infectious disease agent worldwide. The World Health Organization (WHO) set ambitious targets of reducing TB incidence by 90% and deaths by 95% compared with a baseline of 2015 by 2035. In the foreseeable future, the Stop TB Partnership’s Global Plan to End TB (2018-2022) highlights the overarching goal to diagnose and treat 40 million people with TB by 2022 in line with the United Nations High Level Meeting on TB (UNHLM) targets. Treatment of TB infection (TBI) is one of the critical strategies to achieve these global targets.
The Stop TB Partnership’s New Diagnostics Working Group (NDWG), housed at the Foundation for Innovative New Diagnostics (FIND) has a taskforce specifically focused on supporting the goal of disease elimination by addressing the reservoir of TBI and efficiently introducing targeted preventive therapy. The NDWG would like to develop a landscape of tests for TBI led by University College London (UCL).
In this regard, we are inviting manufacturers to take part in a survey. The purpose of this survey is to review the landscape of tests for TBI and identify gaps that need to be filled to facilitate the development and introduction of new tests for TBI. For the purpose of this survey, a test for TB infection is defined as a test that measures immune response to stimulation by Mycobacterium tuberculosis antigens and is intended to be used for identifying individuals to be given treatment of TBI. This survey will be closed at 5PM GMT on 13th July 2020.
Please note that we will publish information provided by manufacturers in a peer-reviewed manuscript. However, submission of data on a new product does not guarantee inclusion in the paper, for example, if the test is not considered as a test for TBI.
Should you have any questions, please feel free to contact Dr. Yohhei Hamada at firstname.lastname@example.org. We appreciate your contribution.